Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.

Cancer research communications·2026
Same author

Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors.

Translational lung cancer research·2026
Same author

Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus study.

BJR artificial intelligence·2026
Same author

Integrating computational chemistry and machine learning to predict KRAS mutation-induced resistance.

bioRxiv : the preprint server for biology·2026
Same author

Erratum: Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung Cancer.

JCO clinical cancer informatics·2026
Same author

Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling.

Science signaling·2025

Related Experiment Video

Updated: Jun 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Dasatinib in solid tumors.

Lori C Kim1, Uwe Rix, Eric B Haura

  • 1University of South Florida College of Medicine, 12902 Magnolia Drive, MCC-GME, Tampa, Florida 33612, USA.

Expert Opinion on Investigational Drugs
|February 2, 2010
PubMed
Summary

Dasatinib, a tyrosine kinase inhibitor, shows promise for treating solid tumors. Clinical trials indicate it is safe and effective for metastatic cancers resistant to standard treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Dasatinib is a potent tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, PDGF, and Src family kinases (SFKs).
  • Currently used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Investigated for efficacy in solid tumors through Phase I and II clinical trials.

Purpose of the Study:

  • To review the clinical efficacy and safety of dasatinib in solid tumors.
  • To identify optimal dosages and applications of dasatinib in solid tumor treatment.
  • To explore the role of Src family kinase (SFK) inhibition in solid malignancies.

Main Methods:

  • Literature search of Phase I/II clinical trials from 1987-2009 using PubMed/MEDLINE, clinicaltrials.gov, and ASCO websites.

Related Experiment Videos

Last Updated: Jun 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

  • Focused on dasatinib's efficacy, dosage, and safety in solid tumors.
  • Included analysis of clinical safety data for dasatinib as a Src inhibitor.

    • Main Results:

    • Dasatinib is being explored in ongoing Phase I and II clinical trials for solid tumors.
    • Understanding of Src activation in tumors and optimal SFK inhibitor use requires further investigation.
    • Clinical safety data indicates dasatinib is generally safe in various solid malignancies.

    Conclusions:

    • Dasatinib is a safe and promising agent for metastatic solid tumors refractory to standard therapies.
    • Further research is needed to fully understand the role of SFK inhibitors in solid tumors.
    • Dasatinib's potential in treating solid malignancies warrants continued clinical investigation.